TY - JOUR
T1 - A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy
AU - Miyazaki, Masaki
AU - Naoki, Katsuhiko
AU - Sato, Takashi
AU - Tanaka, Kyuto
AU - Tsuzuki, Keishi
AU - Yoshida, Shuichi
AU - Tomomatsu, Katsuyoshi
AU - Tasaka, Sadatomo
AU - Soejima, Kenzo
AU - Sayama, Koichi
AU - Asano, Koichiro
PY - 2012/3
Y1 - 2012/3
N2 - A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line (cisplatin+docetaxel-→CPT-11+S-1-→amrubicin- →gemcitabine+vinorelbine-→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th-line treatment with carboplatin (AUC6, day 1 ) + paclitaxel (200 mg/m2, day 1) (Q3W) was administered in March, 2010. The tumor size had been increasing slightly after 2 courses of chemotherapy, although it was within the range of stable disease. Therefore, bevacizumab (15 mg/kg, day 1) was added after the 3rd course of treatment, and the tumor began shrinking obviously with cavity formation. Although the positioning of bevacizumab has not been established after 2nd-line treatment for advanced non-small cell lung carcinoma, we experienced a case of good tumor response by adding the bevacizumab in the middle of the 6th-line chemotherapy.
AB - A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line (cisplatin+docetaxel-→CPT-11+S-1-→amrubicin- →gemcitabine+vinorelbine-→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th-line treatment with carboplatin (AUC6, day 1 ) + paclitaxel (200 mg/m2, day 1) (Q3W) was administered in March, 2010. The tumor size had been increasing slightly after 2 courses of chemotherapy, although it was within the range of stable disease. Therefore, bevacizumab (15 mg/kg, day 1) was added after the 3rd course of treatment, and the tumor began shrinking obviously with cavity formation. Although the positioning of bevacizumab has not been established after 2nd-line treatment for advanced non-small cell lung carcinoma, we experienced a case of good tumor response by adding the bevacizumab in the middle of the 6th-line chemotherapy.
KW - Advanced non-small cell lung carcinoma
KW - Bevacizumab
KW - Chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84861551687&partnerID=8YFLogxK
M3 - Article
C2 - 22421771
AN - SCOPUS:84861551687
SN - 0385-0684
VL - 39
SP - 421
EP - 424
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 3
ER -